AccuMetab™ Human CYP2C9∗ 2 Enzyme, Catalytically Active

CAT#: ITS-0426-YL18
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human CYP2C9∗ 2 variant for precise pharmacogenetic Phase I profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
The CYP2C9∗ 2 allelic variant contains a critical amino acid substitution that severely impairs its catalytic efficiency compared to the wild-type enzyme. In pharmacogenetic studies, this variant is essential for mapping the toxicity risks and delayed clearance rates found in patients with the poor metabolizer phenotype.
Key Features
Engineered pharmacogenetic variant model; Simulates impaired catalytic *2 allele efficiency; Crucial for poor metabolizer toxicity profiling; Supplied in controlled, low-reductase formats
Applications
Drug Metabolism Studies, Phenotype Comparison, Polymorphism Impact
Research Areas
ADME; Pharmacogenetics; Drug-Drug Interactions (DDI)
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry